Maze Finds A Way As Shionogi Signs On To Develop Pompe Drug
Executive Summary
Months after an antitrust lawsuit challenged its deal with Sanofi and raised uncertainty about the future of MZE001, Maze secured a new partner for potentially the first oral Pompe disease drug.